Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENREACH-PDAC-01: KN046 plus nab-paclitaxel and gemcitabine versus placebo plus nab-paclitaxel and gemcitabine in advanced pancreatic cancer
CTR20212934Phase 3Completed
- Sponsor
- Kanion Pharmaceutical
- Start
- Feb 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of erfonrilimab in pancreatic adenocarcinoma (PDAC), sponsored by Kanion Pharmaceutical. Started Feb 2022; status: completed.
02
Drugs
erfonrilimab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20212934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212934.